Back to Authors

Lin, Zhantao

A5036248051 | I168537998

Eli Lilly (United States)

Citations 6

Efficacy of Mirikizumab in Comparison to Ustekinumab in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3 VIVID-1 Study

Zeitschrift für Gastroenterologie | November 27, 2025 | Volume: 62 | Issue: 05 | Pages: e481-e482

10.1055/s-0044-1786891

P68 Mirikizumab versus placebo: histologic inflammation in 5 intestinal segments in randomized controlled phase 3 trial for crohn’s disease participants

Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A129.2-A130

10.1136/gutjnl-2025-bsg.204

S1329 Effects of Mirikizumab versus Placebo on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized, Controlled Phase 3 Trial of Participants With Crohn’s Disease

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S952-S953

10.14309/01.ajg.0001034684.12665.85

S1330 Effects of Mirikizumab and Ustekinumab on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized Controlled Phase 3 Trial of Participants With Crohn’s Disease

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S953-S953

10.14309/01.ajg.0001034688.99618.b9

P115 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate-to-severe Crohn’s disease: results from phase 3 VIVID 1 study

Poster Presentations | July 1, 2024 | Volume: No volume available | Issue: No issue available | Pages: A120.1-A120

10.1136/gutjnl-2024-bsg.197

S982 Association of Histologic-Endoscopic Response and Long-Term Clinical Outcomes: Results From Phase 2 Mirikizumab Trial in Patients With Moderately-to-Severely Active Crohn’s Disease

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S740-S741

10.14309/01.ajg.0000953568.00881.40